Changing therapeutic landscape – The last decade

Cvetkovic, 2006, Rituximab – a review of its use in Non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia, Drugs, 66, 791 Feugier, 2005, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte, J Clin Oncol, 23, 4117, 10.1200/JCO.2005.09.131 Pfreundschuh, 2006, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, 379, 10.1016/S1470-2045(06)70664-7 Habermann, 2006, Rituximab–CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J Clin Oncol, 24, 3121, 10.1200/JCO.2005.05.1003 Sehn, 2005, Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia, J Clin Oncol, 23, 5027, 10.1200/JCO.2005.09.137 Marcus, 2005, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105, 1417, 10.1182/blood-2004-08-3175 Hiddemann, 2005, Blood, 106, 3725, 10.1182/blood-2005-01-0016 Herold, 2007, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study, J Clin Oncol, 25, 1986, 10.1200/JCO.2006.06.4618 Salles, 2004, Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAM FL-2000 randomized trial in 359 patients, Blood, 104, 49a, 10.1182/blood.V104.11.160.160 Schulz, 2007, Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis, J Nat Cancer Inst, 99, 706, 10.1093/jnci/djk152 Glennie, 2007, Mechanisms of killing by anti-CD20 monoclonal antibodies, Mol Immunol, 44, 3823, 10.1016/j.molimm.2007.06.151 Hagenbeek, 2005, Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma, Ann Oncol, 16, 786, 10.1093/annonc/mdi148 Press, 2006, Phase II trial of CHOP chemotherapy followid by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwes Oncology Group Protocol S9911, J Clin Oncol, 24, 4143, 10.1200/JCO.2006.05.8198 Lundin, 2004, Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia, Leukemia, 18, 484, 10.1038/sj.leu.2403258 Kalaycio, 2009, Bendamustine: a new look at an old drug, Cancer, 115, 473, 10.1002/cncr.24057 Schmitz, 2009, Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL), Blood, 114, 168a, 10.1182/blood.V114.22.404.404 Delarue, 2009, R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study, Blood, 114, 169a Vellenga, 2008, Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial, Blood, 111, 537, 10.1182/blood-2007-08-108415 Gisselbrecht, 2009, R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study, J Clin Oncol, 27, 15, 10.1200/jco.2009.27.15_suppl.8509 Reyes, 2005, ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma, N Engl J Med, 352, 1197, 10.1056/NEJMoa042040 Pfreundschuh, 2008, The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL, Blood, 112, 219, 10.1182/blood.V112.11.584.584 Zinzani, 2009, A phase II trial of rituximab–CHOP chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (90Y-IT) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients, Blood, 114, 1065 vanKampen, 2009, Allogeneic stem cell transplantation as salvage therapy in patients with diffuse large B-cell noin-Hodgkin’s lymphoma relapsing after an autologous stem cell transplantation. An analysis of the EBMT registry, Bone Marrow Transpl, 43, S36 Geisler, 2008, Long-term progression-free survival of mantle cell lymphoma after intensive front-line chemotherapy with in vivo-purged stem cell rescue: a nonrandomize phase 2 multicenter study by the Nordic Lymphoma Group, Blood, 112, 2687, 10.1182/blood-2008-03-147025 Kaufmann, 2004, Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma, Blood, 104, 2269, 10.1182/blood-2004-03-1091 Habermann, 2009, Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma, Br J Haematol, 145, 344, 10.1111/j.1365-2141.2009.07626.x O’Connor, 2009, Br J Haematol, 145, 34, 10.1111/j.1365-2141.2008.07466.x Hess, 2009, Phase III study to evaluate temsirolimus compared with investigaotr’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma, J Clin Oncol, 27, 3822, 10.1200/JCO.2008.20.7977 Swerdlow, 2008 Nickelsen, 2009, High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL), Ann Oncol, 20, 1977, 10.1093/annonc/mdp211 D’Amore, 2009, Haematologica, 94, 43 Jaccard, 2008, l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, Ann Oncol, 19, 156 O’Connor, 2009, Phase II–I–II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies, J Clin Oncol, 27, 4357, 10.1200/JCO.2008.20.8470 Olsen, 2007, Phase IIB multicenter trial of vorinostat in pateints with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma, J Clin Oncol, 25, 3109, 10.1200/JCO.2006.10.2434 Piekarz, 2009, Phase II multi-insitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J Clin Oncol, 27, 5410, 10.1200/JCO.2008.21.6150 Hoelzer, 2008, Recent results in the treatment of Burkitt lymphomas, Ann Oncol, 19, 8 Dunleavy, 2008, A prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: a regimen with high efficacy and low toxicity, Ann Oncol, 19, 83 Rummel, 2009, Blood, 114, 168a, 10.1182/blood.V114.22.405.405 van Oers, 2006, I sur. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial, Blood, 108, 3295, 10.1182/blood-2006-05-021113 Forstpointer, 2006, Blood, 108, 4003, 10.1182/blood-2006-04-016725 Brugger, 2004, Clearing minimal residual disease with rituximab consolidation therapy, Semin Oncol, 31, 33, 10.1053/j.seminoncol.2003.12.008 Morschhauser, 2008, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma, J Clin Oncol, 26, 556, 10.1200/JCO.2008.17.2015 Husain, 2007, Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics, Cancer, 110, 809, 10.1002/cncr.22843 Hancock, 2005, Chlorambucil versus observation after anti-Helicobacter therapy in low-grade gastric lymphoma: results of the international LY03 trial, Ann Oncol, 16, 57 Ferreri, 2008, Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (pts) with primary CNS lymphoma (PCNSL), Ann Oncol, 19, 104 Engert, 2009, Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) H10, Blood, 114, 299a, 10.1182/blood.V114.22.716.716 Diehl, 2003, Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease, N Engl J Med, 348, 2386, 10.1056/NEJMoa022473 Validire, 2008, A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin’s lymphoma patients, Anti-Cancer Drugs, 19, 309, 10.1097/CAD.0b013e3282f46aec Meyer, 2005, Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group, J Clin Oncol, 23, 4634, 10.1200/JCO.2005.09.085